Jasper Therapeutics, Inc. (JSPR)

NASDAQ: JSPR · IEX Real-Time Price · USD
2.16
+0.03 (1.41%)
At close: Aug 17, 2022 4:00 PM
2.19
+0.03 (1.39%)
After-hours: Aug 17, 2022 4:43 PM EDT
1.41%
Market Cap 79.24M
Revenue (ttm) n/a
Net Income (ttm) -25.08M
Shares Out 36.69M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,024
Open 2.08
Previous Close 2.13
Day's Range 2.08 - 2.18
52-Week Range 1.73 - 18.88
Beta 0.76
Analysts Buy
Price Target 13.26 (+513.9%)
Earnings Date Aug 11, 2022

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibod... [Read more...]

Industry Biotechnology
Founded 2018
Employees 25
Stock Exchange NASDAQ
Ticker Symbol JSPR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price forecast is 13.26, which is an increase of 513.89% from the latest price.

Price Target
$13.26
(513.89% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

REDWOOD CITY, Calif., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on developing multiple new therapies for the field of stem and cellular ...

All You Need to Know About Jasper Therapeutics, Inc. (JSPR) Rating Upgrade to Buy

Jasper Therapeutics, Inc. (JSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Jasper Therapeutics to Present at the LifeSci Partners 2nd Annual Genetic Medicines Symposium

REDWOOD CITY, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Com...

Jasper Therapeutics to Participate in the William Blair 42nd Annual Growth Stock Conference

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on enabling cures with stem cell therapies, today announced that the Com...

Jasper Therapeutics Announces Annual Virtual Stockholders Meeting to be Held on Thursday, June 23, 2022

REDWOOD CITY, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that its 202...

Jasper Therapeutics Announces Treatment of First Patient in Study of JSP191 Conditioning in Patients with Fanconi Anemia

REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced the dosing of...

Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update

REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on hematopoietic stem cell therapies, today announced first qu...

Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndrom...

Based on positive feedback provided by FDA on key clinical design details Jasper plans to initiate registrational studies in AML and MDS patients Based on positive feedback provided by FDA on key clinic...

Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning A...

REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc., (NASDAQ: JSPR) a biotechnology company focused on hematopoietic stem cell therapies, today announced updated efficacy,...

Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology S...

REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that update...

Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on hematopoietic cell transplant therapies, today announced ...

Jasper Therapeutics Announces Management Changes to Strengthen Leadership Team

REDWOOD CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced changes to ...

Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today a...

Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference

REDWOOD CITY, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Co...

Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer

William Lis to Continue as Chairman, Board of Directors William Lis to Continue as Chairman, Board of Directors

Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & C...

REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic stem cell therapies, today announced that the prelimina...

12 biotech stocks to consider buying now as prospects for the sector brighten this year

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematolog...

REDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on...

Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update

REDWOOD CITY, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced results for ...

Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Li...

2 Biotech Stocks Poised for Jaw-Dropping Growth

These two tiny drugmakers could make early shareholders wealthy.

Other symbols: NRXP

Why Jasper Therapeutics Stock Is Falling Today

Jasper Therapeutics Inc (NASDAQ: JSPR) is trading lower Thursday amid profit taking after the stock rallied roughly 120% on Wednesday. Jasper Therapeutics surged higher Wednesday after Oppenheimer analy...

JSPR Stock: The Bullish Call That Has Biotech Play Jasper Therapeutics Rocketing 105% Today

Jasper Therapeutics (JSPR) stock is taking off on Wednesday thanks to a new bullish call from Oppenheimer analyst Jay Olson. The post JSPR Stock: The Bullish Call That Has Biotech Play Jasper Therapeuti...

Why Jasper Therapeutics Stock Is Jumping Today

A Wall Street investment bank just started following the company with a very upbeat outlook.

Why Jasper Therapeutics Stock Is Soaring Today

Jasper Therapeutics Inc (NASDAQ: JSPR) is surging higher Wednesday after Oppenheimer analyst Jay Olson initiated coverage on the stock with an Outperform rating and announced a price target of $21. The ...